Relmada Therapeutics Inc (RLMD) saw an uptrend of 1282193% in the recent trading with $1790000.0 being its most recent. The current price level -84.94% lower than the highest price of $4.47 marked by the stock while trading over the past 52-weeks, whereas it is 179.99% higher than the lowest price of $0.24 the company dropped to over past 52-weeks. The latest news story on RLMD appeared in (GlobeNewswire) under the title “Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology” on Jun-17-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Hold by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 3.00 for the stock.
Relmada Therapeutics Inc Earnings – What Happened With RLMD
Coming around sales and income figures on RLMD Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Relmada Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 33.19 million. RLMD does have institutional investors; and they hold 25.04% of the stock.
As on 2024-06-30, VANGUARD GROUP INC was the top most holder in Relmada Therapeutics Inc (NASDAQ:RLMD) with an ownership of 1.26 million shares of the company or 16.6593 of the stake worth $3.77 million. The filing also reveals DEEP TRACK CAPITAL, LP as the second largest holder in the company with a control over 16.3686 of the outstanding shares. Its stake is worth $3.7 million for having 1.23 million shares in hand.
VESTAL POINT CAPITAL, LP also came holding a key position in the company during the recent quarter and it now holds 15.9076 of the outstanding shares. With this there are now 55.0 institutions which have possession in RLMD’s shares.
Key Metrics forRLMD
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Relmada Therapeutics Inc has a debt to equity ratio of 0.00.
Technical Analysis of Relmada Therapeutics Inc (NASDAQ:RLMD) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Relmada Therapeutics Inc (RLMD), we notice that the stock’s 20-day average volume is at 483,455 shares. And to end with, RLMD’s 100-day average volume are 1,617,284 shares.
